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Acute renal insufficiency (ARI) after cardiac surgery is a complex and frequent clinical problem. It increases 
short- and long-term mortality, the incidence of post-operative complications such as respiratory infections, 
sepsis, and gastrointestinal bleeding, and intensive care unit (ICU) and hospital lengths of stay.1,2 Identified risk 
factors for post-operative ARI in cardiac surgical patients include pre-operative renal insufficiency, advanced 
age, history of congestive heart failure, diabetes mellitus, recent exposure to nephrotoxic agents such as contrast 
dye, intra-aortic balloon pump, emergency operation, prolonged cardiopulmonary bypass (CPB) time, low 
urinary output during CPB, and need for deep hypothermic circulatory arrest (Figure 1).2,3 
Analysing the pre-operative risk factor trends in cardiac surgery during the 1990-1999 decade in the large, 
voluntary, nationwide STS database, Ferguson et al. showed that the incidence of pre-operative renal 
insufficiency increased from 3.0 to 4.6%. Recently, Swaminathan et al.4 showed that, among coronary artery 
bypass grafting (CABG) patients, the incidence of acute renal failure increased significantly from 1.1 to 4.1%. 
While the proportion of a diagnosis of acute renal failure cases requiring haemodialysis decreased from 15.8 to 
8.7%, the percentage of survivors with post-operative special care requirements increased from 35.5 to 64.5%.5 
Over the last few years, the prognostic importance of mildly elevated pre-operative serum creatinine levels or 
small increases in post-operative creatinine values became apparent, leading to a shift in our understanding of the 
importance of even small degrees of acute kidney injury. Antunes et al.6 reported, among 2122 patients with pre-
operative creatinine serum levels <2.0 mg/dL having CABG and an uncomplicated post-operative course,  a  
mean   increase  of 0.3 mg/dL between   pre-operative (1.0 mg/dL) and maximal post-operative (1.3 mg/dL) 
serum creatinine levels, and a mean reduction of 20 mL/min in the estimated creatinine clearance, from 82 to 62 
mL/min. When compared with pre-operative creatinine levels <1.3 mg/dL, levels of 1.3-1.6 mg/dL and of >1.7 
mg/dL increased the likelihood of developing post-operative renal insufficiency by 5.5 and 14 times, 
respectively.6 A mild elevation (1.3-2.0 mg/dL) of the pre-operative creatinine level significantly increased the 
probability of peri-operative mortality, low cardiac output, haemodialysis, and prolonged hospital length of stay. 
In this study,6 the duration of CBP increased mortality, morbidity, and incidence of renal dysfunction by a factor 
of 1.14 for each 10 min of CPB time. 
Potential reasons for renal dysfunction include cardiovascu lar compromise, prolonged CPB time, increased 
catecholamine level, non-pulsatile flow, hypothermia, renal hypoperfusion, and the induction of inflammatory 
mediators.7 A number of possible strategies aimed at alleviating the development of renal dysfunction during 
cardiac surgery have been evaluated (Figure 2). Techniques that could decrease the incidence of ARI include 
off-pump CABG, minimally invasive surgery, specialized devices designed to reduce atheromatous embolic 
load, and changes in bypass temperature management strategies. Several renoprotective drugs, such as 
dopamine, calcium channel antagonists, loop diuretics, atrial natriuretic peptide, and angiotensin-converting 
enzyme inhibitors, have also been evaluated but mostly yielded conflicting or even negative results. 
Numerous factors may collectively contribute to renal ischaemia and systemic inflammatory responses, resulting 
in generous formation of reactive oxygen species and depletion of endogenous antioxidants.7 Therefore, several 
antioxidant agents, such as cata-lase, superoxide dismutase, dimethyl sulfoxide, and allopurinol, have been tested 
but showed variable effects on renal function, as some improve function whereas others do not. 
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The thiol-modifying agent N-acetyl-L-cysteine (NAC) has been used in a variety of disease states, such as 
paracetamol toxicity, pulmonary oxygen toxicity, and human immunodeficiency virus infection.8   Recently, 
NAC has gained renewed interest and wide use because of its role in the minimization of reperfusion injury after 
acute myocardial infarction and its protective effects on renal function in diabetic patients after contrast dye 
injection.9,10 
The diversity of pharmacological applications of NAC is due to the chemical properties of the cysteinyl thiol 
group of the NAC molecule. NAC is an antioxidant that reacts best with the hydroxyl radical and hypochlorous 
acid but poorly with hydrogen peroxide and the superoxide radical. Experimental studies11 in rats showed that 
NAC, infused at 6 mM/kg 1 h prior to and 1 h following renal ischaemia, significantly reduced the induction of 
the transcription factors c-fos and c-jun in the post-ischaemic kidney, reduced stress-induced protein kinase 
activity, mitigated the loss of renal function, and aided recovery in the post-reperfusion-injured kidney (Figure 
3). NAC-infused animals had a higher glomerular filtration rate at 1 and 7 days after the induction of 
ischaemia.11 
In addition to its antioxidant properties, another mechanism by which NAC might improve renal function is an 
interaction between NAC and nitric oxide (NO). Lessio et al.12 found that NAC blunts the reduction of inducible 
NO synthase expression and NO synthesis caused by cyclosporin in rat renal artery vascular smooth muscle cell 
cultures (Figure 3). NO-independent vasodilatation with NAC has also been reported. 
Attempting to assess whether or not the use of NAC is beneficial during cardiac surgery, Adabag et al.13 have 
reported a systematic review of randomized controlled trials (RCTs) of NAC in adult cardiac surgical patients. 
Ten RCTs, published between 2005 and 2008, were included. Placebo control was used in all but one study, in 
which the control group consisted of patients under usual care. In six of the studies, participants were considered 
to be at high risk for developing ARI. In eight studies, NAC was administered intravenously although there was 
considerable variation in the dose, duration, and route of administration. 
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Figure 2 Surgical techniques and pharmaceutical agents used to decrease the incidence of acute renal 
insufficiency (ARI) after cardiac surgery. CABG, coronary artery bypass grafting; CPB, cardiopulmonary 
bypass; ACE, angiotensin-converting enzyme; ANP, atrial natriuretic peptide. 
 
Figure 3  Experimental effects of NAC in rats. *lnfused at 6 mM/kg 1 h prior to and 1 h following renal 
ischaemia; NO, nitric oxide. 
 
 
The mean age of the 1163 patients included in the meta-analysis was 70 ± 7 years, 71% were males, and 66% 
underwent CABG alone or combined CABG and valve surgery. Primary outcome was ARI, defined as an 
absolute increase >0.5 mg/dL or a relative increase >25% in serum creatinine from baseline within 5 days after 
surgery. Secondary outcomes were maximum change in serum creatinine from baseline within 5 days of surgery, 
need for post-operative haemodialysis, all-cause mortality, and lengths of ICU and hospital stays. 
Overall, NAC did not reduce ARI incidence (35% NAC vs. 37% placebo), while 3.3% of patients required 
haemodialysis and 3% died. There was a trend towards reduced ARI incidence among patients with pre-
operative chronic kidney disease who received NAC, particularly if it was given intravenously. NAC did not 
reduce length of ICU or hospital stay, although the lengths of stay varied considerably between studies. 
Interestingly, in two RCTs, renal function was evaluated 14 and 30 days after surgery, showing similar results 
between NAC and placebo patients. 
Therefore, current evidence does not support the routine use of NAC during cardiac surgery. However, as the 
authors13 correctly pointed out, several limitations of the assessment of the possible role of NAC in post-
operative renal function in cardiac surgical patients should be emphasized. First, the serum creatinine level, used 
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in most studies to measure renal function, is influenced by body square area and body water mass. It often 
overestimates glomerular filtration rate and misses some subclinical kidney dysfunction. Creatinine clearance 
testing is more accurate but requires urine volume and urine creatinine. Cystatin C, another glomerular filtration 
rate marker, is superior to serum creatinine in various selected cases, and proved to be an earlier marker than 
serum creatinine to reflect ARI. Secondly, doses of NAC used, which varied considerably among trials, may 
have been inadequate to counteract the ischaemic insults to the renal tubular epithelial cells induced by CPB. 
In conclusion, post-operative renal failure in cardiac surgery remains a burden on short- and long-term healthcare 
resources. The development of techniques or pharmaceutical agents that could significantly protect the kidneys 
during cardiac surgical procedures is of paramount importance. 
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